The fourth heart valve intervention enterprise invested by Gaoying Capital is minimally invasive Xintong. Micro-invasive Xintong is a high-tech medical device company focusing on the research and development, manufacturing, sales and related technical consulting services of high-end interventional medical devices in the field of heart valves. According to Minimally Invasive Heart Disease, aortic stenosis is one of the most common and serious valvular diseases in the elderly, and the prevalence rate increases significantly with the age of patients. In western countries, the incidence of aortic stenosis is about 2% in people aged 65 and over, and about 4% in people aged 85 and over. Without timely intervention, the median survival time of patients is 2 ~ 3 years. Transcatheter aortic valve replacement (TAVR) is a method of clinical interventional therapy in recent years. Initially, this therapy was designed to provide an ideal alternative treatment for patients with high risk and severe aortic stenosis who could not tolerate aortic valve replacement.
According to the newspaper report, Jianshi Technology will be listed soon. Jianshi Technology is a high-tech enterprise specializing in cardiovascular interventional therapy. Its main products include coronary stent, coronary balloon dilatation catheter and percutaneous aortic valve replacement system.